Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.33 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2888368 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL2885557 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL2885558 | 1.00 | ALDH1A1 (0.45) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL6107095 | 0.87 | HSD11B1 (0.38) | ALDH1A1TSHRHSD11B1MT-CO2ALOX5 | |
| SCHEMBL6107867 | 0.87 | HSD11B1 (0.41) | ALDH1A1TSHRHSD11B1 | |
| SCHEMBL6107480 | 0.87 | HSD11B1 (0.38) | ALDH1A1TSHRHSD11B1MT-CO2ALOX5 | |
| SCHEMBL6107873 | 0.87 | HSD11B1 (0.41) | ALDH1A1TSHRHSD11B1 | |
| SCHEMBL6107096 | 0.87 | HSD11B1 (0.38) | ALDH1A1TSHRHSD11B1MT-CO2ALOX5 | |
| SCHEMBL6107872 | 0.87 | HSD11B1 (0.41) | ALDH1A1TSHRHSD11B1 | |
| SCHEMBL6107091 | 0.87 | HSD11B1 (0.38) | ALDH1A1TSHRHSD11B1MT-CO2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099673-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK SHARP & DOHME CORP. | 2010-04-22 | — | — | US | disclosed |
| EP-2124568-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008088744-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099673-A1 | DECAHYDROQUINOLINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | ALDH1A1 2406/4885TSHR 709/4885KDM4E 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.